FDA clears Ultragenyx (RARE) gene therapy after 48-week trial—what changed for GSDIa patients?
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical Inc. (RARE) reported that the U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr, DTX401) to treat adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). Approval is based on a 48-week randomized, double-blind, placebo-controlled Phase 3 study in 46 participants, which showed a statistically significant reduction in cornstarch requirements for DTX401-treated patients at a 1.0 x 10^13 GC/kg dose (p<0.001). Ultragenyx agreed to a post-marketing program that will follow 50 commercially treated patients and 20 control patients for at least 2 years, with broader disease monitoring over 10 years to further characterize safety, fasting tolerance, and other clinical outcomes.
Positive
- FDA granted accelerated approval for GENGLYCOS (DTX401) in GSDIa patients eight years and older, providing Ultragenyx with a new commercial gene therapy product.
- Pivotal Phase 3 trial in 46 participants showed a statistically significant reduction in cornstarch requirements (p<0.001), supporting the therapy’s clinical efficacy.
- A long-term Disease Monitoring Program will track up to 10 years of safety and efficacy data, potentially strengthening the therapy’s evidence base over time.
Negative
- None.
Filing Explained
The post-marketing program’s 20-person control group will consist of patients who sought GENGLYCOS treatment but could not receive it because of anti-AAV8 antibodies; previously treated trial participants will also be followed in the 10-year disease-monitoring program.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Approval pathway: Accelerated approval
Eligible patient age: Eight years and older
Phase 3 participants: 46 participants
+5 more
8 metrics
Approval pathway
Accelerated approval
FDA pathway granted for GENGLYCOS in GSDIa
Eligible patient age
Eight years and older
Age range for adult and pediatric patients with GSDIa
Phase 3 participants
46 participants
Randomized, double-blind, placebo-controlled GlucoGene study population
DTX401 dose
1.0 x 10^13 GC/kg
Dose level used in the Phase 3 GlucoGene study
mITT population
44 participants
Participants with efficacy data within the Week 48 analysis period
Commercial-treated patients in DMP
50 patients
Number of open-label commercial treatment patients in post-marketing study
Control patients in DMP
20 patients
Control group of patients unable to receive GENGLYCOS due to anti-AAV8 antibodies
Long-term monitoring period
10 years
Duration the GSDIa Disease Monitoring Program will evaluate patients
Key Terms
accelerated approval, glycogen storage disease type Ia, modified intention-to-treat, open-label commercial treatment, +2 more
6 terms
accelerated approval regulatory
"FDA granted accelerated approval for GENGLYCOS"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
glycogen storage disease type Ia medical
"patients eight years and older with glycogen storage disease type Ia"
An inherited metabolic disorder in which the body cannot release stored sugar (glycogen) into usable glucose because a key enzyme is missing or not working, causing low blood sugar, enlarged liver, and other complications. For investors this matters because it creates a small but urgent market for treatments and diagnostics—successful drugs, gene therapies, or regulatory approvals can materially change a company’s prospects and valuation due to high medical need and limited existing options.
modified intention-to-treat medical
"There were 44 participants in the modified intention-to-treat (mITT) population"
Modified intention-to-treat is a way of analysing clinical trial results that starts from the original randomized groups but excludes some participants according to rules set before the trial (for example people who never received any study treatment or lack key baseline data). It sits between a strict 'count everyone' approach and a 'only perfect participants' analysis. Investors pay attention because these choices can change reported effectiveness and safety, which can affect regulatory views and market reactions—like judging a recipe after removing certain ingredients.
open-label commercial treatment medical
"two years of safety and efficacy clinical data from open-label commercial treatment of 50 patients"
anti-AAV8 antibodies medical
"cannot be treated with GENGLYCOS due to the presence of anti-AAV8 antibodies"
Disease Monitoring Program medical
"through enhancement of its existing GSDIa Disease Monitoring Program"
FAQ
What did Ultragenyx (RARE) announce regarding GENGLYCOS (DTX401)?
Ultragenyx announced that the FDA granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr, DTX401) to treat adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). The decision was based on positive Phase 3 clinical data.
Which patients can receive GENGLYCOS according to the Ultragenyx (RARE) update?
GENGLYCOS is approved for adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). Eligibility in the post-marketing study excludes patients with anti-AAV8 antibodies, who will instead form part of the control group.
What clinical data supported the FDA’s accelerated approval for Ultragenyx (RARE)?
The accelerated approval is supported by a 48-week, randomized, double-blind, placebo-controlled Phase 3 study in 46 participants, where DTX401 at 1.0 x 10^13 GC/kg significantly reduced cornstarch requirements (p<0.001) versus placebo, indicating meaningful clinical benefit.
What post-marketing commitments did Ultragenyx (RARE) agree to for GENGLYCOS?
Ultragenyx agreed to collect at least two years of safety and efficacy data from 50 commercially treated patients and 20 control patients via its GSDIa Disease Monitoring Program, plus broader follow-up over 10 years to assess long-term outcomes.
How will the Ultragenyx (RARE) Disease Monitoring Program be used for GENGLYCOS?
The GSDIa Disease Monitoring Program will follow previously treated trial participants and new commercial patients for up to 10 years, assessing reductions in cornstarch burden, fasting tolerance, glucose control, and other clinical measures in real-world practice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
